- Home
- Companies
- Finch Therapeutics Group, Inc.
- Products
- Finch - Model FIN-211 - Microbiome ...
Finch - Model FIN-211 - Microbiome Therapeutics for Autism Spectrum Disorder (ASD)
FIN-211 is an orally administered, Enriched Consortia product candidate designed to address both the gastrointestinal (GI) and behavioral symptoms of ASD. ASD is a behaviorally defined condition characterized by difficulties with interpersonal interaction, communication, and repetitive or restrictive patterns of behavior and activities. A subset of individuals with ASD experience significant GI symptoms, with the most common GI symptom being constipation.
The Unmet Need
1:54 children affected by ASD in the US (4.6 million individuals in the US)
>30% of individuals with ASD suffer from GI symptoms
>$100 billion spent on care for individuals with ASD in the US each year
Zero FDA-approved therapies for the core symptoms of ASD, as well as a lack of effective treatments for GI symptoms
FIN-211 for ASD
Oral delivery of a complete microbiome community that is enriched with targeted microbes
Designed to address GI and behavioral symptoms by targeting multiple ASD-relevant pathways
Development program builds off mechanistic data and five investigator-sponsored, proof-of-concept clinical studies showing improvement in both GI and behavioral symptoms following microbiota transplantation